Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study

Laura Ordoñez-Boschetti, Roberto Rey, Ana Cruz, Arijit Sinha, Tracy Reynolds, Nadina Frider, Regina Alvarenga, Laura Ordoñez-Boschetti, Roberto Rey, Ana Cruz, Arijit Sinha, Tracy Reynolds, Nadina Frider, Regina Alvarenga

Abstract

Introduction: Fingolimod 0.5 mg is an orally active sphingosine 1-phosphate receptor modulator approved for use in adults with relapsing multiple sclerosis (MS). The efficacy and safety profile of fingolimod has been well characterized in a large clinical development program. Here, we report the safety and tolerability of fingolimod in relapsing-remitting MS (RRMS) patients from Latin America.

Methods: A total of 162 patients with RRMS, predominantly from Latin American countries (138/162), were enrolled in this 16-week, single treatment arm, open-label, multi-center study. Unlike the phase III pivotal studies, this study permitted enrollment of patients with controlled diabetes, certain cardiac and pulmonary conditions, older age, and higher baseline Expanded Disability Status Scale. All patients were monitored clinically for a minimum of 6 hours after the first dose. Safety and tolerability assessments were based on adverse events, clinically notable laboratory abnormalities, vital signs, ophthalmic examinations, and electrocardiograms.

Results: Overall, the safety and tolerability profile was consistent with that reported previously in phase 3 studies and the FIRST study. Adverse events (AEs) were predominantly mild (n = 49, 35.5%) or moderate (n = 27, 19.6%). Three patients (2.2%) discontinued fingolimod due to AEs. Infections were reported in 33 patients (23.9%) and were predominantly mild in nature (n = 28, 20.3%). Increases in alanine aminotransferase enzymes of ≥3, ≥5 and ≥10 upper limit of normal were reported in five (3.7%), three (2.2%) and one (0.7%) patients, respectively. Hypertension cases (n = 3; 2.2%) did not result in treatment discontinuation and were controlled with antihypertensive therapy. Following first-dose administration, the majority of patients (90.6%) were discharged at 6 h. During the first-dose monitoring, 5 cases of bradycardia were reported; none required extended monitoring or treatment for symptomatic bradycardia.

Conclusion: The first dose of fingolimod 0.5 mg was well tolerated in RRMS patients from Latin America. The overall safety profile was clinically manageable and consistent with previous fingolimod studies.

Funding: Novartis.

Trial registration: ClinicalTrials.gov #NCT01497262.

Figures

Fig. 1
Fig. 1
Hourly mean change in heart rate (HR) in 6 h following first dose and at 4 months. SD standard deviation

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221–1231. doi: 10.1016/S0140-6736(02)08220-X.
    1. Multiple Sclerosis International Federation. Atlas of MS. 2013. . Accessed 21 May 2015.
    1. Correale J. MS in Latin America. Int MS J. 2008;15:3–5.
    1. Luetic G. MS in Latin America. Int MS J. 2008;15:6–11.
    1. Ojeda E, Diaz-Cortes D, Rosales D, Duarte-Rey C, Anaya JM, Rojas-Villarraga A. Prevalence and clinical features of multiple sclerosis in Latin America. Clin Neurol Neurosurg. 2013;115:381–387. doi: 10.1016/j.clineuro.2012.11.028.
    1. Amezcua L, Lund BT, Weiner LP, Islam T. Multiple sclerosis in Hispanics: a study of clinical disease expression. Mult Scler. 2011;17:1010–1016. doi: 10.1177/1352458511403025.
    1. Corona T, Roman GC. Multiple sclerosis in Latin America. Neuroepidemiology. 2006;26:1–3. doi: 10.1159/000089230.
    1. Correale J, Abad P, Alvarenga R, et al. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. J Neurol Sci. 2014;339:196–206. doi: 10.1016/j.jns.2014.02.017.
    1. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124–1140. doi: 10.1056/NEJMoa052643.
    1. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–556. doi: 10.1016/S1474-4422(14)70049-3.
    1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415. doi: 10.1056/NEJMoa0907839.
    1. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. doi: 10.1056/NEJMoa0909494.
    1. Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses. Adv Ther. 2014;31:1072–1081. doi: 10.1007/s12325-014-0154-4.
    1. Fragoso YD, Arruda CC, Arruda WO, et al. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis. Arq Neuropsiquiatr. 2014;72:712–714. doi: 10.1590/0004-282X20140102.
    1. Vergara Soto E, Uribe San Martín R, Ciampi Díaz E, et al. Seguridad De La Primera Dosis De Fingolimod Administrado Bajo Vigilancia Ambulatoria En El Centro De Esclerosis Múltiple De La Pontifi cia Universidad Católica De Chile. VIII Latin American Congress of Multiple Sclerosis (LACTRIMS); 2014.
    1. Kuperman G, Nunez V, Mattiazi M, et al. Cardiac safety profile during first-dose monitoring period of fingolimod (Gilenya) treatment in patients with relapsing remiting MS: data from the Argentinean registry (REAL). Interim Results (P3.250). Neurology. 2015;84(14 Supplement).
    1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703.
    1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice. 1996. . Accessed 21 May 2015.
    1. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. 2015. . Accessed 30 June 2015.
    1. Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014;261:267–276. doi: 10.1007/s00415-013-7115-8.
    1. Kappos L, Comi G, Palace J, et al. Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study. (P336). European Neurologial Society (ENS). 2012.
    1. Camm J, Hla T, Bakshi R, Brinkmann V. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014;168:632–644. doi: 10.1016/j.ahj.2014.06.028.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera